tbuckley/cabot-search huggingface dataset:
Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial
Authors: Seigo Kitano, Masafumi Inomata, Junki Mizusawa, Hiroshi Katayama, Masahiko Watanabe, Seiichiro Yamamoto, Masaaki Ito, Shuji Saito, Shoichi Fujii, Fumio Konishi, Yoshihisa Saida, Hirotoshi Hasegawa, Tomonori Akagi, Kenichi Sugihara, Takashi Yamaguchi, Tadahiko Masaki, Yosuke Fukunaga, Kohei Murata, Masazumi Okajima, Yoshihiro Moriya, Yasuhiro Shimada
Journal: The Lancet. Gastroenterology & hepatology (2017)
ST405 NDM-5 producing Escherichia coli in Northern Italy: the first two clinical cases
Authors: I. Bitar, A. Piazza, S. Gaiarsa, L. Villa, P. Pedroni, E. Oliva, E. Nucleo, L. Pagani, A. Carattoli, R. Migliavacca
Journal: Clinical Microbiology and Infection (2017)
Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice
Authors: Huihui Li, Tenzin Choesang, Weili Bao, Huiyong Chen, Maria Feola, Daniel Garcia-Santos, Jie Li, Shuming Sun, Antonia Follenzi, Petra Pham, Jing Liu, Jinghua Zhang, Prem Ponka, Xiuli An, Narla Mohandas, Robert E. Fleming, Stefano Rivella, Guiyuan Li, Yelena Z. Ginzburg
Journal: Blood (2017)
MAPK-Activation in CD34+ CML Stem Cells Induced by Selective Abl-Inhibitors Is Not Observed Using the Combined Src/Abl-Inhibitor Dasatinib.
Authors: Paul La Rosee, Nicolai Haertel, Thomas Klag, Heiko Konig, Ruediger Hehlmann, Andreas Hochhaus
Journal: Blood (2007)
Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS.
Authors: Stefan Deneberg, Michael Grövdal, Monika Jansson, Verena I. Gaidzik, Andrea Corbacioglu, Hareth Nahi, Sofia Bengtzen, Konstanze Döhner, Christer Paul, Eva Hellström-Lindberg, Sören Lehmann
Journal: Blood (2008)
ANKHD1, a New Ankyrin-Repeat Protein, Binds to SIVA and May Modulate ROS Generation, Cell Cycle and Apoptosis Signaling in Cancer Cells
Authors: Fabiola Traina, Patrícia Cristina Rodrigues, Mariana Lazarini, Paulo Roberto Moura Lima, Fernando F. Costa, Sara T.O. Saad
Journal: Blood (2008)
Doctors could do more to recoup costs from overseas patients for NHS, say MPs
Authors: Adrian O’Dowd
Journal: BMJ (2017)

Doctors and NHS trusts could and should do more to tackle the currently “chaotic” approach to recovering costs from overseas patients who receive NHS services, MPs have said.

MPs on the parliamentary Public Accounts Committee published a critical report on NHS treatment for overseas patients on 1 February, in which they demanded that the Department of Health produce an action plan by June on how it will increase the amount recovered from overseas visitors.1

Some treatments, such as appointments with general practitioners and emergency care, are currently free to all patients, and some patients, such as refugees, are exempt from charges. But most hospital care is chargeable for overseas visitors.

The committee said in its report …
A Trial of Extending Hemodialysis Hours and Quality of Life
Authors: Meg J. Jardine, Li Zuo, Nicholas A. Gray, Janak R. de Zoysa, Christopher T. Chan, Martin P. Gallagher, Helen Monaghan, Stuart M. Grieve, Rajesh Puranik, Hongli Lin, Josette M. Eris, Ling Zhang, Jinsheng Xu, Kirsten Howard, Serigne Lo, Alan Cass, Vlado Perkovic
Journal: Journal of the American Society of Nephrology (2017)

The relationship between increased hemodialysis hours and patient outcomes remains unclear. We randomized (1:1) 200 adult recipients of standard maintenance hemodialysis from in-center and home-based hemodialysis programs to extended weekly (≥24 hours) or standard (target 12–15 hours, maximum 18 hours) hemodialysis hours for 12 months. The primary outcome was change in quality of life from baseline assessed by the EuroQol 5 dimension instrument (3 level) (EQ-5D). Secondary outcomes included medication usage, clinical laboratory values, vascular access events, and change in left ventricular mass index. At 12 months, median weekly hemodialysis hours were 24.0 (interquartile range, 23.6–24.0) and 12.0 (interquartile range, 12.0–16.0) in the extended and standard groups, respectively. Change in EQ-5D score at study end did not differ between groups (mean difference, 0.04 [95% confidence interval, −0.03 to 0.11]; P =0.29). Extended hours were associated with lower phosphate and potassium levels and higher hemoglobin levels. Blood pressure (BP) did not differ between groups at study end. Extended hours were associated with fewer BP-lowering agents and phosphate-binding medications, but were not associated with erythropoietin dosing. In a substudy with 95 patients, we detected no difference between groups in left ventricular mass index (mean difference, −6.0 [95% confidence interval, −14.8 to 2.7] g/m 2 ; P =0.18). Five deaths occurred in the extended group and two in the standard group ( P =0.44); two participants in each group withdrew consent. Similar numbers of patients experienced vascular access events in the two groups. Thus, extending weekly hemodialysis hours did not alter overall EQ-5D quality of life score, but was associated with improvement in some laboratory parameters and reductions in medication burden. (Clinicaltrials.gov identifier: NCT00649298).
MPTH-03IMPLEMENTATION AND UTILIZATION OF GENOMIC PROFILING IN A COMMUNITY NEURO-ONCOLOGY PRACTICE
Authors: Nicholas Blondin
Journal: Neuro-Oncology (2015)

Genomic profiling has rapidly become an essential component of brain tumor classification.This technology can be used to detect genetic alterations that may drive the growth of a tumor, and can be used to identify potential targeted treatment options.Herein we present the results of genomic profiling of brain tumor samples obtained over the past two years at our institution.In our patient population, CDKN2A/B loss is frequently found in glioblastoma patients, suggesting that CDK4/6 inhibitors such as palbociclib may have a potential therapeutic role in adult glioblastoma.Other important mutations such as IDH mutations, EGFRvIII and alterations in the PI3k/akt/mTOR pathway can be detected with genomic profiling and lead to individualized treatment strategies.
Stroke Risk Factors, Genetics, and Prevention
Authors: Amelia K. Boehme, Charles Esenwa, Mitchell S.V. Elkind
Journal: Circulation Research (2017)

Stroke is a heterogeneous syndrome, and determining risk factors and treatment depends on the specific pathogenesis of stroke. Risk factors for stroke can be categorized as modifiable and nonmodifiable. Age, sex, and race/ethnicity are nonmodifiable risk factors for both ischemic and hemorrhagic stroke, while hypertension, smoking, diet, and physical inactivity are among some of the more commonly reported modifiable risk factors. More recently described risk factors and triggers of stroke include inflammatory disorders, infection, pollution, and cardiac atrial disorders independent of atrial fibrillation. Single-gene disorders may cause rare, hereditary disorders for which stroke is a primary manifestation. Recent research also suggests that common and rare genetic polymorphisms can influence risk of more common causes of stroke, due to both other risk factors and specific stroke mechanisms, such as atrial fibrillation. Genetic factors, particularly those with environmental interactions, may be more modifiable than previously recognized. Stroke prevention has generally focused on modifiable risk factors. Lifestyle and behavioral modification, such as dietary changes or smoking cessation, not only reduces stroke risk, but also reduces the risk of other cardiovascular diseases. Other prevention strategies include identifying and treating medical conditions, such as hypertension and diabetes, that increase stroke risk. Recent research into risk factors and genetics of stroke has not only identified those at risk for stroke but also identified ways to target at-risk populations for stroke prevention.
C-Myb Restrains Megakaryopoiesis through the Hsa-MiR-486-3p-Driven Down-Regulation of C-Maf
Authors: Elisa Bianchi, Jenny Bulgarelli, Giorgia Sacchi, Samantha Ruberti, Ruggiero Norfo, Sebastiano Rontauroli, Valentina Pennucci, Roberta Zini, Simona Salati, Zelia Prudente, Sergio Ferrari, Alessandro M. Vannucchi, Rossella Manfredini
Journal: Blood (2014)
Immunologic Effects of the Renin-Angiotensin System
Authors: Steven D. Crowley, Nathan P. Rudemiller
Journal: Journal of the American Society of Nephrology (2017)

Inappropriate activation of the renin-angiotensin system (RAS) exacerbates renal and vascular injury. Accordingly, treatment with global RAS antagonists attenuates cardiovascular risk and slows the progression of proteinuric kidney disease. By reducing BP, RAS inhibitors limit secondary immune activation responding to hemodynamic injury in the target organ. However, RAS activation in hematopoietic cells has immunologic effects that diverge from those of RAS stimulation in the kidney and vasculature. In preclinical studies, activating type 1 angiotensin (AT 1 ) receptors in T lymphocytes and myeloid cells blunts the polarization of these cells toward proinflammatory phenotypes, protecting the kidney from hypertensive injury and fibrosis. These endogenous functions of immune AT 1 receptors temper the pathogenic actions of renal and vascular AT 1 receptors during hypertension. By counteracting the effects of AT 1 receptor stimulation in the target organ, exogenous administration of AT 2 receptor agonists or angiotensin 1–7 analogs may similarly limit inflammatory injury to the heart and kidney. Moreover, although angiotensin II is the classic effector molecule of the RAS, several RAS enzymes affect immune homeostasis independently of canonic angiotensin II generation. Thus, as reviewed here, multiple components of the RAS signaling cascade influence inflammatory cell phenotype and function with unpredictable and context-specific effects on innate and adaptive immunity.
Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis.
Authors: Uday Popat, Gabriela Rondon, Amin Alousi, Paolo Anderlini, Borje Andersson, Chitra Hosing, Marcos de Lima, Stefan Ciurea, Sergio Giralt, Partow Kebriaei, Yago Nieto, Issa Khouri, Muzaffar H Qazilbash, Roy Jones, Richard Champlin
Journal: Blood (2009)
Can Elimination of Total Body Irradiation (TBI) in Conditioning Regimens for Autologous Stem Cell Transplantation (SCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma Decrease the Risk of Secondary AML/MDS(sAML/MDS)? A Retrospective Case-Control Study at the University of Nebraska Medical Center.
Authors: Lori J. Maness, F. R. Loberiza, W. Sanger, M. P. DeVetten, P. Bierman, G. Bociek, J. O. Armitage, J. M. Vose
Journal: Blood (2005)
The global gag rule and what to do about it
Authors: Scott L Greer, Sarah D Rominski
Journal: BMJ (2017)

Since Ronald Reagan was president, banning and unbanning the use of US aid to support agencies that discuss abortion or refer patients to abortion services has been a partisan tradition. Republican presidents make a point of ordering the ban in their first days in office, and Democrats make a point of rescinding it. In this, as in many other ways, Donald Trump is an ordinary Republican. On his third day in office he signed his new version of the executive order.1

The order is known as the “Mexico City policy,” after its first enunciation in 1984 in Mexico City, or as the “global gag rule,” because it effectively blocks US support to any organisation that even discusses abortion as a form of family planning. US support for organisations that provide abortion has been illegal by statute since …
Mesenchymal Stem Cells Promote Survival of Leukemic Cells Via Integrin-Linked Kinase (ILK)-Dependent Akt and STAT3 Activation: Implications for Leukemia Therapy.
Authors: Yoko Tabe, Linhua Jin, Gordon B. Mills, Yuko Tsutsumi-Ishii, Michael Andreeff, Marina Konopleva
Journal: Blood (2004)
MPTH-31CO-EXISTENCE OF TWO TERT PROMOTER REGION SOMATIC POINT MUTATIONS IN A RECURRENT GLIOBLASTOMA
Authors: Raymund Yong, Huaien Wang
Journal: Neuro-Oncology (2015)

BACKGROUND: Mutations in the promoter region of the telomerase reverse transcriptase gene (TERT) occur at a frequency of greater than 80% in primary GBM. The two most observed TERT promoter mutations in primary GBM, C250T and C228T, each create a de novo transcription factor consensus binding site, upregulating TERT mRNA expression, and are thought to occur in a mutually exclusive fashion. Here we describe the case of a recurrent GBM found to harbor both the C250T and C228T mutations. METHODS: A 57-year-old woman who presented with right hemiparesis and expressive dysphasia was found to have a left frontal contrast-enhancing tumor. She underwent subtotal resection, which revealed primary GBM, and went on to receive standard chemoradiation combined with intra-arterial and intravenous bevacizumab as part of an experimental protocol. She returned with disease progression ten months later and underwent second resection. Fresh tumor was preserved for histopathology, DNA extraction, and was cultured in both serum-free and adherent conditions. RESULTS: Sequencing of tumor DNA revealed that almost all cells harbored the C250T mutation, while a small fraction of cells harbored the C228T mutation. In adherent conditions at early passage, the C250T mutation continued to predominate while there was slight enrichment of C228T. Early and late passage spheres uniformly exhibited the C228T mutation, while C250T was undetectable. Late passage adherent cells exhibited only C228T and could form spheres when transferred into serum-free conditions. All cultures were genotyped and compared to the patient's germline DNA to exclude contamination. CONCLUSIONS: Our results suggest that ongoing convergent evolution gave rise to the C228T mutation in a clone of tumor cells that did not harbor the prevailing C250T mutation of the original tumor. The clone containing C228T exhibited greater proliferation and superior sphere-forming ability in vitro compared to clones containing C250T, and may have been selected through treatment.
T Cell Toll-Like Receptors Play a Critical Role in Graft-Versus-Host Disease and Graft-Versus-Leukemia
Authors: Masanori Kadowaki, Kazutoshi Aoyama, Motoko Koyama, Yukimi Sakoda, Kiyoshi Takeda, Chen Liu, Koichi Akashi, Mitsune Tanimoto, Takanori Teshima
Journal: Blood (2008)
Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial
Authors: Gesine Bug, Andreas Burchert, Eva-Maria Wagner, Nicolaus Kroeger, Zuzana Jedlickova, Saskia Gueller, Stephan Metzelder, Andrea Wolf, Peter Bader, Sabine Huenecke, Hubert Serve, Oliver G. Ottmann
Journal: Blood (2015)
Transfer of Specific T Cell Clones with Graft-Versus-Leukemia (GVL) Activity from Donor to Recipient in Stem Cell Transplantation: Identification, Quantification and Characterization.
Authors: Katayoun Rezvani, David A. Price, Jason Brenchley, Yasemin Kilical, Emma Gostick, Andrew K. Sewell, Giuseppe Sconocchia, Roger Kurlander, Daniel C. Douek, John Barrett
Journal: Blood (2004)
Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
Authors: Matthew A. Lunning, Julie Vose, Nathan Fowler, Loretta Nastoupil, Jan A. Burger, William Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher Flowers, Jonathon B. Cohen, Susan Blumel, Myra Miguel, Kathy Cutter, Emily K. Pauli, Ryan Handy, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O'Brien
Journal: Blood (2015)
Acute Ischemic Stroke Therapy Overview
Authors: Luciana Catanese, Joseph Tarsia, Marc Fisher
Journal: Circulation Research (2017)

The treatment of acute ischemic stroke has undergone dramatic changes recently subsequent to the demonstrated efficacy of intra-arterial (IA) device-based therapy in multiple trials. The selection of patients for both intravenous and IA therapy is based on timely imaging with either computed tomography or magnetic resonance imaging, and if IA therapy is considered noninvasive, angiography with one of these modalities is necessary to document a large-vessel occlusion amenable for intervention. More advanced computed tomography and magnetic resonance imaging studies are available that can be used to identify a small ischemic core and ischemic penumbra, and this information will contribute increasingly in treatment decisions as the therapeutic time window is lengthened. Intravenous thrombolysis with tissue-type plasminogen activator remains the mainstay of acute stroke therapy within the initial 4.5 hours after stroke onset, despite the lack of Food and Drug Administration approval in the 3- to 4.5-hour time window. In patients with proximal, large-vessel occlusions, IA device-based treatment should be initiated in patients with small/moderate-sized ischemic cores who can be treated within 6 hours of stroke onset. The organization and implementation of regional stroke care systems will be needed to treat as many eligible patients as expeditiously as possible. Novel treatment paradigms can be envisioned combining neuroprotection with IA device treatment to potentially increase the number of patients who can be treated despite long transport times and to ameliorate the consequences of reperfusion injury. Acute stroke treatment has entered a golden age, and many additional advances can be anticipated.
Processes of care in curative therapy for gastric cancer: A RAND/UCLA appropriateness study.
Authors: Savtaj Singh Brar, Calvin Law, Robin S. McLeod, Lawrence Frank Paszat, Lucy K. Helyer, Rajini Seevaratnam, Roberta Cardoso, Alyson L. Mahar, Lavanya Yohanathan, Alina Bocicariu, Natalie G. Coburn
Journal: Journal of Clinical Oncology (2012)

104 Background: Processes of care in curative therapy for gastric cancer are ill-defined, have significant variations and may impact patient outcomes. Methods: A multi-disciplinary expert panel (16 physicians, 6 countries) scored 595 scenarios using the RAND/UCLA Appropriateness Methodology. Appropriateness was scored from 1 (highly inappropriate) to 9 (highly appropriate). Median appropriateness scores from 1-3 were considered inappropriate, 4-6 uncertain, and 7-9 appropriate. Agreement was reached when 11 of 16 panelists scored the statement similarly. If a statement was agreed to be appropriate, it was given a necessity score in the same manner. Results: Open gastrectomy was considered appropriate for all patients and necessary for patients with N2-3 disease, while laparoscopic gastrectomy was appropriate for patients with T1-2 N0 disease. D1 lymph node dissection (LND) was considered appropriate for T1 N0 disease. For all others, D2 LND was considered appropriate and necessary. It was appropriate to assess at least 15 LN. Intraoperative pathologic assessment of the proximal margin was considered appropriate for gross margins &lt;5 cm or T3/T4 lesions. If the margin was positive on frozen section, re-resection of the stomach or abdominal esophagus was considered appropriate for N1-3 disease and necessary for N0 disease. Curative resection was appropriate if a patient presented with perforation. Neoadjuvant chemotherapy was considered appropriate for patients who presented with T1-2 N2-3 or T3-4 N0-3 disease with minor symptoms but not with major symptoms. Adjuvant chemoradiotherapy was considered appropriate and necessary for patients with T1-2 N1-3 or T3-4 N0-3 disease. No adjuvant therapy was considered appropriate for patients with T1N0 disease. Conclusions: The above criteria have been found to be appropriate and necessary for the curative treatment of patients with gastric cancer and may be used to improve processes and quality of care.
The Dose of CD34+ Cells Negatively Impacts the Outcome of Patients Treated with Genoidentical Allo SCT Prepared with a Reduced Intensity Conditioning (RIC).
Authors: Didier Blaise, Laure Farnaut, Catherine Faucher, Sabine Furst, Jean El Cheikh, Hughes Delavallade, Ladaique Patrick, Norbert Vey, Reda Bouabdallah, Anne Marie Stoppa, Claude Lemarie, Boris Calmel, Mohamad Mohty, Christian Chabannon
Journal: Blood (2007)
NIMG-19NEURORADIOLOGIC CHARACTERISTICS OF ASTROBLASTOMA: A META-ANALYSIS BASED ON 127 PATIENTS IN 59 PUBLICATIONS
Authors: Danielle Cunningham, Lisa Lowe, Lei Shao, Natasha Acosta
Journal: Neuro-Oncology (2015)

BACKGROUND AND AIMS: Astroblastoma is a rare tumor of uncertain origin most commonly presenting in the cerebral hemispheres of children and young adults. The literature has a few case reports and series regarding its radiologic features. This meta-analysis is the largest review of imaging findings to date and serves to differentiate astroblastoma from other neoplasms. METHODS: A PubMed search identified reports of astroblastoma with neuroimaging findings. Data collected included patient age, sex, tumor location, morphology, calcifications, calvarial changes and findings on computed tomography (CT) and magnetic resonance imaging (MRI), including diffusion weighted imaging (DWI). RESULTS: Patient age range at diagnosis was 0-70 years (mean 18 years; median 14 years) with a female:male ratio of 8:1. Of 127 cases, 65 reported CT, 78 reported MRI and 47 reported both CT and MRI findings. Tumor location was supratentorial in 96% (122/127), superficial in 71% (47/66), well-demarcated in 96% (79/82), cystic-solid in 93% (79/85), and enhancing in 99% (77/78). On CT, 84% (26/31) of astroblastomas were hyperattenuated. Calcifications were present in 77% (27/35), with five cases also reporting adjacent calvarial erosion. Astroblastomas were hypointense on T1 in 58% (25/43) and hypointense on T2 in 50% (23/46). Peritumoral edema was present in 79% (38/48) of cases, but typically described as slight. Few cases reported DWI sequences, with 100% (4/4) showing hyperintensity and decreased ADC values indicating restricted diffusion. CONCLUSION: Most astroblastomas occur in young females. 96%, 71%, 96%, 93%, 99% are supratentorial, superficial, well-defined, cystic-solid, and enhancing, respectively. On CT, most are hyperattenuated, have calcifications, and if superficial, may erode adjacent bone. On MRI, astroblastomas are characteristically dark on both T1 and T2 with 100% of cases showing restricted diffusion on DWI.
Allogeneic Stem Cell Transplantation From Unrelated One-Antigen HLA-Mismatched Donor, Increases Acute II-IV Gvhd Incidence without Interfering with Other Post-Transplant Complications
Authors: Eva De Berranger, Louis Terriou, Valérie Coiteux, Leonardo Magro, Françoise Dufossé, Jean-Pierre Jouet, Ibrahim Yakoub-Agha
Journal: Blood (2010)